Institution
Barking, Havering and Redbridge University Hospitals NHS Trust
Healthcare•London, United Kingdom•
About: Barking, Havering and Redbridge University Hospitals NHS Trust is a healthcare organization based out in London, United Kingdom. It is known for research contribution in the topics: Randomized controlled trial & Population. The organization has 407 authors who have published 269 publications receiving 5084 citations.
Topics: Randomized controlled trial, Population, Reproductive health, Mortality rate, Prospective cohort study
Papers
More filters
••
Charité1, Leiden University2, Maastricht University3, Dokuz Eylül University4, Ruhr University Bochum5, University of Córdoba (Spain)6, University of Paris7, Sun Yat-sen University8, Ege University9, University of Alberta10, Ghent University11, University of Copenhagen12, Fırat University13, Barking, Havering and Redbridge University Hospitals NHS Trust14, Chung Shan Medical University15
TL;DR: The new ASAS classification criteria for axial SpA can reliably classify patients for clinical studies and may help rheumatologists in clinical practice in diagnosing axial spondyloarthritis in those with chronic back pain.
Abstract: Objective: To validate and refine two sets of candidate criteria for the classification/diagnosis of axial spondyloarthritis (SpA). Methods: All Assessment of SpondyloArthritis international Society (ASAS) members were invited to include consecutively new patients with chronic (⩾3 months) back pain of unknown origin that began before 45 years of age. The candidate criteria were first tested in the entire cohort of 649 patients from 25 centres, and then refined in a random selection of 40% of cases and thereafter validated in the remaining 60%. Results: Upon diagnostic work-up, axial SpA was diagnosed in 60.2% of the cohort. Of these, 70% did not fulfil modified New York criteria and, therefore, were classified as having “non-radiographic” axial SpA. Refinement of the candidate criteria resulted in new ASAS classification criteria that are defined as: the presence of sacroiliitis by radiography or by magnetic resonance imaging (MRI) plus at least one SpA feature (“imaging arm”) or the presence of HLA-B27 plus at least two SpA features (“clinical arm”). The sensitivity and specificity of the entire set of the new criteria were 82.9% and 84.4%, and for the imaging arm alone 66.2% and 97.3%, respectively. The specificity of the new criteria was much better than that of the European Spondylarthropathy Study Group criteria modified for MRI (sensitivity 85.1%, specificity 65.1%) and slightly better than that of the modified Amor criteria (sensitivity 82.9, specificity 77.5%). Conclusion: The new ASAS classification criteria for axial SpA can reliably classify patients for clinical studies and may help rheumatologists in clinical practice in diagnosing axial SpA in those with chronic back pain. Trial registration number: NCT00328068.
2,704 citations
••
University of Leeds1, Blackpool Victoria Hospital2, University College Dublin3, Radboud University Nijmegen4, University of Toronto5, University of Utah6, Royal United Hospital7, University of Washington8, Stanford University9, Federal University of Paraná10, Federal University of Rio de Janeiro11, LSU Health Sciences Center Shreveport12, Johns Hopkins University13, University of Buenos Aires14, Seoul National University15, University of Molise16, University of Cagliari17, University of Queensland18, Federal University of Uberlandia19, University of California, Davis20, Barking, Havering and Redbridge University Hospitals NHS Trust21, University of Naples Federico II22, Hospital Italiano de Buenos Aires23, University of Amsterdam24, Military Hospital25, Katholieke Universiteit Leuven26
TL;DR: Two new composite measures to assess disease activity in PsA have been developed by multiple linear regression and empirically, utilising physician-defined cut-offs for disease activity, and area under the receiver operating curves (AUC) were generally smaller.
Abstract: Objective To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression (psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28). Results 161/503 (32%) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95% CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease (psoriasis area and severity index >10) both nonparametric and AUC curve statistics were nonsignificant for all measures. Conclusions Two new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.
252 citations
••
TL;DR: This work discovers and validate six previously unknown risk loci for PBC and used pathway analysis to identify JAK-STAT/IL12/IL27 signalling and cytokine–cytokine pathways, for which relevant therapies exist.
Abstract: Primary biliary cirrhosis (PBC) is a classical autoimmune liver disease for which effective immunomodulatory therapy is lacking. Here we perform meta-analyses of discovery data sets from genome-wide association studies of European subjects (n=2,764 cases and 10,475 controls) followed by validation genotyping in an independent cohort (n=3,716 cases and 4,261 controls). We discover and validate six previously unknown risk loci for PBC (Pcombined<5 × 10(-8)) and used pathway analysis to identify JAK-STAT/IL12/IL27 signalling and cytokine-cytokine pathways, for which relevant therapies exist.
245 citations
••
Newcastle University1, Northumbria Healthcare NHS Foundation Trust2, Newcastle upon Tyne Hospitals NHS Foundation Trust3, Massachusetts Institute of Technology4, Glasgow Caledonian University5, University of Leeds6, Barking, Havering and Redbridge University Hospitals NHS Trust7, London North West Healthcare NHS Trust8, University of Glasgow9, Northumbria University10, University of Oxford11, NHS Greater Glasgow and Clyde12, University of East London13, University of Sunderland14
TL;DR: Robo-assisted training and EULT did not improve upper limb function after stroke compared with usual care for patients with moderate or severe upper limb functional limitation, and these results do not support the use of robot- assisted training as provided in this trial in routine clinical practice.
232 citations
••
Institute of Cancer Research1, University of Salford2, Cardiff University3, Copenhagen University Hospital4, University Health Network5, St James's University Hospital6, Queen's University7, University College London8, Université de Montréal9, University of Wolverhampton10, East Kent Hospitals University Nhs Foundation Trust11, Barking, Havering and Redbridge University Hospitals NHS Trust12, Royal Surrey County Hospital13, Southampton General Hospital14, Maidstone and Tunbridge Wells NHS Trust15, University Hospitals Birmingham NHS Foundation Trust16, Maidstone Hospital17, Guy's Hospital18, Belfast Health and Social Care Trust19, Northwood University20, Hillingdon Hospital21, Mount Vernon Hospital22, University of Hull23
TL;DR: The initial results do not support routine administration of adjuvant radiotherapy after radical prostatectomy, and an observation policy with salvage radiotherapy for PSA biochemical progression should be the current standard after radical Prostate cancer.
200 citations
Authors
Showing all 410 results
Name | H-index | Papers | Citations |
---|---|---|---|
Neil P. Shah | 66 | 306 | 26263 |
James Duffy | 27 | 115 | 2682 |
Christopher Rao | 25 | 90 | 2548 |
William B. English | 24 | 52 | 2720 |
Shafiul Haque | 22 | 200 | 2220 |
Dilip Mukherjee | 20 | 62 | 1285 |
Coziana Ciurtin | 20 | 130 | 2265 |
Paul E Pfeffer | 19 | 73 | 1240 |
Sesh Kamal Sunkara | 19 | 41 | 1838 |
Euthalia Roussou | 15 | 27 | 4330 |
Bhik Kotecha | 15 | 53 | 998 |
Shobhit Arya | 14 | 26 | 1133 |
Sergio Coda | 12 | 36 | 613 |
Salman Haider | 11 | 16 | 810 |
Anastasia Stamatopoulou | 10 | 16 | 353 |